July 12, 2016


  •  join-a-study

    The Michigan Alzheimer’s Disease Center conducts and supports innovative memory and aging research that seeks to:

    • Identify disease modifying treatments
    • Understand disease mechanisms in AD and other dementias
    • Define biomarkers for early and accurate detection
    • Devise effective coping strategies for individuals with memory loss and their care-partners

    Despite tremendous recent advances in understanding Alzheimer’s disease and related dementias, there’s still much we do not know about the causes of dementing disorders and how to slow down or prevent them altogether.  Clinicians and scientists alike need to take a broad, fresh view of the causes of dementia and the potential routes to better therapy.  Our Center is deeply committed to this task. Building from the rich expertise present across the University campus, we strive to foster cutting-edge research toward a better understanding and better treatment of Alzheimer’s disease, Lewy Body Disease, frontotemporal dementia and other related disorders.

    Areas of research emphasis include investigations of the quality control machinery that counters aggregated proteins in dementia, imaging studies that seek to improve our ability to diagnose disease earlier and more accurately, and explorations of the interplay between metabolic disorders (e.g. obesity, diabetes) and Alzheimer’s disease.  A key part of our mission is to make connections – linking scientists to scientists, clinicians to scientists, volunteers to studies, even programs to programs.  Through these connections, we can lower the barriers to solving the challenging problems associated with dementia.

  • Join a Study

    Now is the time to join our research team. Research participation is a generous gift – a gift that can be shared with future generations as we pave the way to new discoveries in treatment and prevention. Research participation contributes to the discovery of new ways to diagnose, treat and support people with Alzheimer’s disease or a related disorder.

    We are currently seeking research volunteers experiencing early signs of memory changes as well as healthy older adults. We understand that participating in research is not always an easy decision. Individuals and their families should carefully consider all of the possible benefits and risks before agreeing to participate.

    If you are interested in participating in research, please complete a Research Volunteer Form to get started. Once completed, please mail or email to Holly Bunker at hlbunker@med.umich.edu or 2101 Commonwealth Blvd, Ste D, Ann Arbor, MI 48105. Please contact Holly Bunker at 734-615-5319 with any questions. We thank you for considering participating in research!

    Currently Enrolling Studies

    University of Michigan Memory and Aging Project (UM-MAP): The University of Michigan Memory and Aging Project (UM-MAP) is the Michigan Alzheimer’s Disease Center’s main observational, longitudinal study.  The study investigates changes related to memory and thinking over time so that researchers can learn more about normal aging and neurodegenerative diseases. Participants in UM-MAP can be seen at both our Ann Arbor and Detroit locations. There is modest compensation for participation. All participants must have a family member or close friend as their study partner to accompany them to visits.

    Medication Studies

    A Study of LY3154207 in Participants with Parkinson's Disease Dementia (PRESENCE Study)

    Evaluating the safety and efficacy of LY3154207 (positive allosteric modulator of the D1 receptor) on cognition in patients with mild-moderate Parkinson’s disease dementia. Study is looking for adults with Parkinson’s disease and dementia age 40-85, with well-controlled blood pressure and a reliable caregiver who is able to be present for certain visits. Contact Braden DeWeese at deweeseb@med.umich.edu or 734-615-5495 for more information.

    PRESENCE Trial Flyer

    Troriluzole Trial for Alzheimer's Disease (T2 Protect Study)

    Evaluating the safety and efficacy of BHV-4157 in Patients with Mild to Moderate Alzheimer’s Disease. Study is looking for participants ages 50-85 with a reliable and available study partner to attend study visits. Eligible participants should be receiving a stable dose of FDA-approved AD medication(s) for at least 3 months prior to screening. For Ann Arbor, contact Courtney Graft at ccgraft@med.umich.edu or (734) 763-2211. For Lansing, contact Dennis Shubitowski at dennis.shubitowski@hc.msu.edu or 517-884-2286.

    T2 Study Flyer

    Dementia with Lewy Bodies Phosphodiesterase Inhibitor Assessment (DELPHIA Study)

    Evaluating the efficacy (as well as safety and tolerability) of E2027 on cognition in subjects with dementia with Lewy bodies (DLB).  The study is looking for participants age 50-85 with probable DLB who have a reliable and available study partner to attend the 10 study visits over 22 weeks. Participants will receive either E2027 or placebo. Contact Jackie Dobson at jdobs@med.umich.edu or 734-998-8400.

    Phase 3 Study of AVP-786

    This study is evaluating the efficacy, safety, and tolerability of AVP-786 compared to placebo for the treatment of agitation in patients with dementia of the Alzheimer's type. Patients are enrolled for 16 weeks with up to 4 weeks for screening and 12 weeks of treatment (either placebo or AVP-786). At the conclusion of this study, patients are offered to continue in the next phase of the study to evaluate the long-term safety and maintenance of efficacy for AVP-786. The length is approximately 56 weeks and all patients are on varying blinded doses of AVP-786. This study is enrolling participants in Lansing. Contact Dennis Shubitowski at dennis.shubitowski@hc.msu.edu or 517-884-2286.

    Memory Training Studies

    Promoting adaptive neuroplasticity in mild cognitive impairment (Merit)

    Examining the benefits of two types of treatments for memory impairment – cognitive rehabilitation and electrical brain stimulation. Study is looking for adults with mild cognitive impairment over the age of 50. Contact Julia Laing at laingjul@med.umich.edu or 734-764-4709.

    Stimulation to Undermine Dementia (STUD)

    Investigating the potential benefits of varying ‘doses’ of non-invasive electrical brain stimulation combined with cognitive rehabilitation. Study is looking for adults with mild cognitive impairment over the age of 55. Contact Rachael Snyder at rlsnyder@med.umich.edu or 734-936-7360.

    Neuroimaging and Biomarker Studies

    Alzheimer's Disease Neuroimaging Initiative 3 (ADNI 3)

    Determining the relationships among clinical, cognitive, imaging, genetic, and biomarker characteristics of the entire spectrum of AD as it progresses from a preclinical stage to very mild symptoms to mild cognitive impairment (MCI) to dementia. Study is looking for adults age 55-90 with normal cognition, MCI, or mild AD. Contact Lisa Zbizek-Nulph at lzbizek@med.umich.edu or 734-232-1199.

    Brain Relationships Among Information, Neuroprocessing, and Self-Management (BRAINS)

    This study is looking at factors related to health information behavior, brain activity, and self-management in African American women.  The study is looking for African American women 21-64 years of age diagnosed with hypertension and diabetes (or with elevated blood sugar levels).  Contact Lenette Jones at lenettew@umich.edu or 734-763-1371.

    Examination of the earliest symptoms and biomarkers of FTLD MAPT carriers

    Investigating the earliest clinical features of frontotemporal dementia in an effort to improve early detection of the disease. Study is looking for adults age 18 and older with a family member who has frontotemporal dementia. Contact Stephen Campbell at stepcamp@med.umich.edu or 734-763-2361.

    Lewy Body Dementia Biomarkers

    Investigating new brain imaging approaches that investigators hope will identify protein accumulations in the brain of individual patients with PD-related dementia. This study is looking for adults age 55 and older with Parkinson’s disease dementia (PDD), Dementia with Lewy Bodies (DLB), or Alzheimer’s disease with at least one symptom of DLB. Contact Christine Minderovic at cmindero@med.umich.edu or 734-998-8420.

    LBD Biomarkers Study Flyer

    Ocular Imaging in Dementia

    The purpose of this study is to determine if imaging of the eye can be used to provide investigators new information about diagnosing AD and FTD as well as monitoring the progression of these diseases. This study is recruiting adults age 45 – 80 who are cognitively normal or have been diagnosed with either AD or FTD. This study will take place at the University of Michigan Kellogg Eye Center and University Hospital in Ann Arbor. Contact Dr. Omar Moinuddin, MD at omoinudd@med.umich.edu or 734-232-8404.

    Ocular Imaging Study Flyer

    Risk Evaluation and Education of Alzheimer’s Disease – the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)

    The purpose of this study is to learn about the best ways to communicate educational information about amyloid imaging brain scans and risk information about the chance of developing AD. Study is enrolling cognitively normal adults ages 65 to 80, have/had at least one first-degree relative (i.e., parent or siblings) with Alzheimer’s disease. Contact Lan Le at revealstudy@umich.edu or 734-615-2422. This study team sees participants in Ann Arbor and Detroit.

    Subjective Cognitive Impairment – A Sign of Incipient Alzheimer’s Disease?

    Longitudinal study investigating functional and structural brain changes in healthy older adults with and without cognitive complaints.  Study is looking for adults age 60 or older with worrisome memory complaints or a diagnosis of MCI.  Contact the Wayne State University Connect Lab at connectlab@wayne.edu or 313-664-2670.  This study team is recruiting for visits at Wayne State University in Detroit.

    Lifestyle Intervention Studies

    University of Michigan Memory and Aging Project (UM-MAP)

    Investigating changes in cognitive functioning over time to learn more about normal aging and neurodegenerative diseases. Study is looking for adults with or without cognitive changes over the age of 55. Contact Holly Bunker at hlbunker@med.umich.edu or 734-615-5319. This study team sees participants in Ann Arbor and Detroit.

    Advancing Reliable Measurement in Alzheimer's Disease and Cognitive Aging (ARMADA)

    Testing a new set of measurements – the NIH Toolbox for Assessment of Neurological and Behavioral Function – for their ability to detect early signs of cognitive decline and to differentiate among cognitive health and cognitive illness. Participants must be part of – or willing to be part of –  the University of Michigan Memory and Aging Project (UM-MAP) in addition to this study. The study is looking for adults with normal cognition, mild cognitive impairment, or Alzheimer’s disease age 65-85.  Contact Yonatan Kahsay at ykahsay@med.umich.edu or 734-936-8281.  This study team sees participants in Ann Arbor and Detroit.

    Developing a Personalized System to Assist Aging Drivers

    The goal of this study is to understand driving behavior and factors that might influence how older adults drive. Being able to drive safely allows older adults to do many life-long activities that are important to them. Despite the importance of this topic, there has been little research studying factors that impact older adults in different driving scenarios. This study is designed to collect information on older adults’ driving over multiple days and on factors, such as physiological responses, that might influence their safe driving. This information will provide an important knowledge base for the future development of personalized systems to promote safe driving for older adults.

    Eligible participants will be asked to complete appointments at the University of Michigan Neuropsychology Clinic (UM Neuropsychology) and the University of Michigan Transportation Research Institute (UMTRI). First, you will be asked to complete one appointment at UM Neuropsychology where you will use a computer-based driving simulator and complete a brief computer-based assessment of thinking and problem solving. This appointment will take up to 2 hours. Next, you will be asked to drive your own vehicle for five separate days while we collect on-road driving data. To do this we will ask you to visit UMTRI each morning and evening. During the first visit to UMTRI, we will install an in-vehicle data collection device and a small camera system in your vehicle. You will then be asked to drive as you normally would that day, returning to UMTRI in the evening to allow study staff to turn the data collection devices off. On each of the remaining four driving days you will return to UMTRI in the morning to turn on the data collection devices and return in the evening to turn them off. You will be asked to complete a survey while the devices are being installed in your vehicle, a brief survey when you return to UMTRI each evening, and a short interview while the devices are being removed from your vehicle at the end of the fifth driving day. The first UMTRI appointment will take up to 2 hours and the remaining UMTRI appointments will take approximately 15 minutes. Finally, for the simulator appointment and on-road driving, you will be asked to wear a chest belt and a special set of gloves that will measure physiological data like heart rate. Participants will be paid a total of $250 – distributed across the study visits.

    Participation criteria: Age 65 or older; have a valid driver’s license; have been actively driving for at least one year; drive at least three times per week; drive a car that is model year 1996 or newer; are able to visit UMTRI two times per day during the five days of on-road driving data collection in your own vehicle over a two-week period.

    Contact: Natcha Srimaneerungroj at snatcha@med.umich.edu or 734-764-6169.

    Encephalographic Computerized Assessment (ELECTRA)

    Testing the utility of electroencephalographic (EEG) and computerized testing in identifying the first signs of dementia in at-risk African Americans. ELECTRA is a collaborative project between Wayne State University and the University of Michigan. Participants must be part of (or willing to be part of) the University of Michigan Memory and Aging Project (UM-MAP) in addition to this study. Eligible participants will be cognitively normal African Americans age 65 or older who are concerned about their memory and thinking. The study team sees participants in Detroit at Wayne State University; travel to Ann Arbor may be required as part of the UM-MAP study. Contact the ELECTRA study team at sshair@med.umich.edu or 313-577-1692.

    Enhancing Safe Mobility among Older Drivers

    Investigating how older drivers might change their driving behavior over time and what influences any changes that might occur. Study is looking for both healthy adults and those with MCI age 65 or older. Contact Jennifer Zakrajsek at jzak@umich.edu or 734-615-4740.

    Internet-Based Conversational Engagement Clinical Trial (I-CONECT)

    Investigating potential benefits of social engagement in healthy older adults, using regular phone or video chat conversations to improve health and well-being. Study is looking for generally healthy adults over the age of 75 in the Detroit metropolitan area who are socially isolated or would like to have more opportunities to talk with others. Contact the study team at I-CONECT_UM@ohsu.edu or 734-647-2676. This study involves phone and video chat visits in the home.

    Caregiver Studies

    Adaptive Coping Engagement with Caregivers of Black Older Adults with Dementia (ACE Project)

    The ACE Project is investigating caregiver mental health, physical health, and social supports with the aim of developing culturally tailored programming. This study is seeking African American/ Black caregivers of persons with dementia or cognitive impairments to complete a survey. Contact Dr. Sheria Robinson-Lane at grices@med.umich.edu or 734-764-9280.  This study team will meet participants in the home.

    Tele-Savvy: An Online Psychoeducation Program for Dementia Family Caregivers

    The purpose of this study is to test the psychoeducational program "Tele-Savvy”, which is an internet-based group education program developed from an in-person program called Savvy Caregiver. Study is looking for informal caregivers (family/friends) of persons living with Alzheimer’s disease or another dementia over the age of 18.  Contact Natasha Spoden at spoden@ohsu.edu or 503-494-6370.  This study occurs via phone and computer (computer or mobile device with internet is necessary).


  • Brain Donation Program

    There are over 13 million Americans living with a brain disease or disorder. To find treatments and cures, researchers must study the human brain. The Michigan Brain Bank provides individuals and families an opportunity to contribute to this research effort.

    Donated brains are collected and stored by the Michigan Brain Bank to help scientists around the world advance the understanding of brain disease and disorders. You can make a difference and help future generations by generously donating your brain to the Michigan Brain Bank.

    If you are interested in donating to the Michigan Brain Bank or would like more information, please call Matthew Perkins at 734-647-7648 or visit the Michigan Brain Bank website.

  • Publications


    Marino S, Zhou N, Zhao Y, Wang L, Wu Q, Dinov I. HDDA: DataSifter: Statistical Obfuscation of Electronic Health Records and Other Sensitive Datasets. Journal of Statistical Computation and Simulation. 2019, Vol 89:2, 249-271, doi: 10.1080/00949655.2018.1545228.


    Brenowitz WD, Han F, Kukull WA, Nelson PT. Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. Neurobiol Aging. 2018 Feb;62:64-71. doi: 10.1016/j.neurobiolaging.2017.10.004 PMID: 29107848 PMCID: PMC5743774

    Cheran G, Silverman H, Manoochehri M, Goldman J, Lee S, Wu L, Cines S, Fallon E, Kelly BD, Olszewska DA, Heidebrink J, Shair S, Campbell S, Paulson H, Lynch T, Cosentino S, Huey ED. Psychiatric symptoms in preclinical behavioural-variant frontotemporal dementia in MAPT mutation carriers. J Neurol Neurosurg Psychiatry. 2018 Jan 20:jnnp-2017. doi: 10.1136/jnnp-2017-317263 PMID: 29353234

    Christensen KD, Uhlmann WR, Roberts JS, et al. A randomized controlled trial of disclosing genetic risk information for Alzheimer’s disease via telephone. Genetics in Medicine. 2018.  20(1), 132-41. doi: 10.1038/gim.2017.103. PMID: 28726810 PMCID: PMC5897910

    Dinov ID, Palanimalai S, Khare A, Christou N.  Randomization‐Based Statistical Inference: A Resampling and Simulation Infrastructure. Teach Stat.2018 Summer;40(2):64-73. PMID: 30270947. PMCID: PMC6155997

    Goyal, D, Tjandra, D, Migrino, R, Syed, Z, Giordani, B & Wiens, J. Characterizing heterogeneity in the progression of Alzheimer's disease using longitudinal clinical and neuroimaging biomarkers. 2018. PMID: 30456290. PMCID: PMC6234900.

    Green KM, Glineburg MR, Kearse MG, Flores BN, Linsalata AE, Fedak SJ, Goldstrohm AC, Barmada SJ, Todd PK. RAN translation at C9orf72-associated repeat expansions is selectively enhanced by the integrated stress response. Nat Commun. 2017 Dec 8;8(1):2005. doi: 10.1038/s41467-017-02200-0 PMID: 29222490 PMCID: PMC5722904

    Howanitz, J., Carney, K.O, Lichtenberg, P.A., Donlan, A., Sugarman, M & Malek, K. Neurocognitive Engagement Therapy: An Innovative Rehabilitation Approach for those with Cognitive Impairment. Topics in Geriatric Rehabilitation. January/March 2018 - Volume 34 - Issue 1 - p 36–47

    Kotagal V, Spino C, Bohnen NI, Koeppe R, Albin RL. Serotonin, β-amyloid, and cognition in Parkinson disease. Ann Neurol. 2018 Apr 17. doi: 10.1002/ana.25236 PMID: 29665066

    Lichtenberg PA, Ocepek-Welikson K, Ficker LJ, Gross E, Rahman-Filipiak A, Teresi JA. Conceptual and Empirical Approaches to Financial Decision-making by Older Adults: Results from a Financial Decision-making Rating Scale. Clinical gerontologist. 2018 January;41(1):42-65. doi: 10.1080/07317115.2017.1367748 PMID: 29077531 PMCID: PMC5766370

    Lin M, Gong P, Yang T, Ye J, Albin RL, Dodge HH. Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer disease and associated disorders. 2018 January;32(1):18-27. PubMed PMID: 29227306; PubMed Central PMCID: PMC5854492.

    Park SK, Arslan F, Kanneganti V, Barmada SJ, Purushothaman P, Verma SC, Liebman SW. Overexpression of a conserved HSP40 chaperone reduces toxicity of several neurodegenerative disease proteins. Prion. 2018 Jan 31:1-7. doi: 10.1080/19336896.2017.1423185. PMID: 29308690 PMCID: PMC5871033

    Rahman-Filipiak AM, Giordani B, Heidebrink J, Bhaumik A, Hampstead BM. Self- and informant-reported memory complaints: Frequency and severity in cognitively intact individuals and those with mild cognitive impairment and neurodegenerative dementias. J Alzheimers Dis 2018; 65 (3) 1011–1027. PMID:30124444

    Sharkey LM, Safren N, Pithadia AS, Gerson JE, Dulchavsky M, Fischer S, Patel R, Lantis G, Ashraf N, Kim JH, Meliki A, Minakawa EN, Barbada S, Ivanova MI, Paulson HL (2018). Mutant UBQLN2 promotes toxicity by modulating intrinsic self-assembly. 

    Silbert LC, Lahna D, Promjunyakul NO, Boespflug E, Ohya Y, Higashiuesato Y, Dodge HH (2018). Risk Factors Associated with Cortical Thickness and White Matter Hyperintensities in Dementia Free Okinawan Elderly. J Alzheimers Dis, 63(1), 365-372. doi:10.3233/JAD-171153 PMID: 29578488 PMCID: PMC5900560

    Tarraf W, Criqui MH, Allison MA, Wright CB, Fornage M, Daviglus M, Kaplan RC, Davis S, Conceicao AS, González HM. Ankle brachial index and cognitive function among Hispanics/Latinos: Results from the Hispanic Community Health Study/Study of Latinos. Atherosclerosis. 2018 Apr 1;271:61-9. doi: 10.1016/j.atherosclerosis.2018.02.016 PMID: 29459267

    Tiernan CT, Mufson EJ, Kanaan NM, Counts SE. Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease. J Neuropathol Exp Neurol. 2018; 77(3):246-259. doi: 10.1093/jnen/nlx120. PMID: 29378005

    Uhlmann WR, Roberts JS. Ethical issues in neurogenetics. In D Geschwind, C Klein, H Paulson (Eds.), Handbook of Clinical Neurology. 2018. 147, 23-36. Elsevier. doi: 10.1016/B978-0-444-63233-3.00003-8. PMID: 29325614 PMCID: PMC5896012

    Wang B, Zeng L, Merillat SA, Fischer S, Ochaba J, Thompson LM, Barmada SJ, Scaglione KM, Paulson HL. The ubiquitin conjugating enzyme Ube2W regulates solubility of the Huntington's disease protein, huntingtin. Neurobiol Dis. 2018 Jan;109(Pt A):127-136. doi: 10.1016/j.nbd.2017.10.002. PMID: 28986324

    Weden MM, Shih RA, Kabeto MU, Langa KM. Secular Trends in Dementia and Cognitive Impairment of U.S. Rural and Urban Older AdultsAm J Prev Med. 2018 Feb;54(2):164-172. doi: 10.1016/j.amepre.2017.10.021 PMID: 29246677 PMCID: PMC5783777

    Weintraub S, Besser L, Dodge HH, Teylan M, Ferris S, Goldstein FC, Giordani B, Kramer J, Loewenstein D, Marson D, Mungas D, Salmon D, Welsh-Bohmer K, Zhou XH, Shirk SD, Atri A, Kukull WA, Phelps C, Morris JC. Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer disease and associated disorders. 2018 January;32(1):10-17. PubMed PMID: 29240561; PubMed Central PMCID: PMC5821520.

    Weskamp K, Barmada SJ. TDP43 and RNA instability in amyotrophic lateral sclerosis. Brain Res. 2018 Jan 29. pii: S0006-8993(18)30023-4. doi: 10.1016/j.brainres.2018.01.015. PMID: 29395044


    Al-Ramahi I, Giridharan SSP, Chen YC, Patnaik S, Safren N, Hasegawa J, de Haro M, Wagner Gee AK, Titus SA, Jeong H, Clarke J, Krainc D, Zheng W, Irvine RF, Barmada S, Ferrer M, Southall N, Weisman LS, Botas J, Marugan JJ. Inhibition of PIP4Kγ ameliorates the pathological effects of mutant huntingtin protein. Elife. 2017 Dec 26;6. pii: e29123. doi: 10.7554/eLife.29123 PMID: 29256861 PMCID: PMC5743427

    Albin RL. Mitigating the burden of neurological disease. Annals of neurology. 2017 Aug;82(2):315. doi: 10.1002/ana.25001 PMID: 28752897 PMCID: PMC5870892.

    Albin RL. Polyglutamine inclusion body toxicity. Movement disorders : official journal of the Movement Disorder Society. 2017 December;32(12):1686. doi: 10.1002/mds.27226 PMID: 29119663 PMCID: PMC5744902

    Ankuda CK, Harris J, Ornstein K, Levine DA, Langa KM, Kelley AS. Caregiving for Older Adults with Obesity in the United States. J Am Geriatr Soc. 2017 Sep;65(9):1939-1945. doi: 10.1111/jgs.14918 PMID: 28449347 PMCID: PMC5603353

    Ankuda CK, Maust DT, Kabeto MU, McCammon RJ, Langa KM, Levine DA. Association Between Spousal Caregiver Well-Being and Care Recipient Healthcare Expenditures. J Am Geriatr Soc. 2017 Oct;65(10):2220-2226. doi: 10.1111/jgs.15039 PMID: 28836269 PMCIDPMC5762126

    Anstey KJ, Peters R, Clare L, Lautenschlager NT, Dodge HH, Barnes DE, Shahar S, Brodaty H, Rees G. Joining forces to prevent dementia: The International Research Network On Dementia Prevention (IRNDP). International psychogeriatrics. 2017 November;29(11):1757-1760. PMID: 28899450 PMCID: PMC5873600.

    Basal LA, Yan Y, Shen Y, Haacke EM, Mehrmohammadi M, Allen MJ.Oxidation-Responsive, EuII/III-Based, Multimodal Contrast Agent for Magnetic Resonance and Photoacoustic Imaging. ACS Omega. 2017 Mar 31, 2(3): 800-805. doi: 10.1021/acsomega.6b00514. PMID: 28393130 PMCID: PMC5377279

    Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ. Biomarkers for the Early Detection and Progression of Alzheimer's Disease. Neurotherapeutics. 2017 Jan,14(1): 35-53. doi: 10.1007/s13311-016-0481-z. PMID: 27738903 PMCID: PMC5233625

    Crosson B, Hampstead BM, Krishnamurthy LC, Krishnamurthy V, McGregor KM, Nocera JR, Roberts S, Rodriguez AM, Tran SM. Advances in Neurocognitive Rehabilitation Research from 1992 to 2017: The Ascension of Neural Plasticity. Neuropsychology. 2017 Aug 31. doi: 10.1037/neu0000396 PMID: 28857600 PMCID: PMC5788715

    Dodge HH, Zhu J, Hughes TF, Snitz BE, Chang CH, Jacobsen EP, Ganguli M. Cohort effects in verbal memory function and practice effects: a population-based study.  International Psychogeriatrics. 2017 Jan, 29(1): 137-148. doi: 10.1017/S1041610216001551. PMID: 27725002 PMCID: PMC5177461

    Dodge HH, Zhu J, Woltjer R, Nelson PT, Bennett DA, Cairns NJ, Fardo DW, Kaye JA, Erten-Lyons D, Mattek N, Schneider JA, Silbert LC, Xiong C, Yu L, Schmitt FA, Kryscio RJ, Abner EL. Risk of incident clinical diagnosis of AD-type dementia attributable to pathology confirmed vascular disease. Alzheimer's & Dementia. Alzheimer's and Dementia. 2017, 13(6): 613–623. doi: 10.1016/j.jalz.2016.11.003  PMID: 28017827 PMCID: PMC5466467

    Davis MA, Guo C, Sol K, Langa KM, Nallamothu BK. Trends and Disparities in the Number of Self-reported Healthy Older Adults in the United States, 2000 to 2014. JAMA internal medicine. 2017 November 1;177(11):1683-1684. doi: 10.1001/jamainternmed.2017.4357 PMID: 28975206 PMCID: PMC5753793

    Gardner RC, Langa KM, Yaffe K. Subjective and objective cognitive function among older adults with a history of traumatic brain injury: A population-based cohort study. PLoS Med. 2017 Mar 7, 14(3): e1002246. doi: 10.1371/journal.pmed.1002246. PMID: 28267747 PMCID: PMC5340352

    Green KM, Glineburg MR, Kearse MG, Flores BN, Linsalata AE, Fedak SJ, Goldstrohm AC, Barmada SJ, Todd PK. RAN translation at C9orf72-associated repeat expansions is selectively enhanced by the integrated stress response. Nature communications. 2017 December 8;8(1):2005. PubMed PMID: 29222490; PubMed Central PMCID: PMC5722904.

    Ginsberg SD, Malek-Ahmadi MH, Alldred MJ, Che S, Elarova I, Chen Y, Jeanneteau F, Kranz TM, Chao MV, Counts SE, Mufson EJ. Selective decline of neurotrophin and neurotrophin receptor genes within CA1 pyramidal neurons and hippocampus proper: Correlation with cognitive performance and neuropathology in mild cognitive impairment and Alzheimer's disease. Hippocampus. 2017 Sept 9. doi:10.1002/hipo.22802. doi: 10.1002/hipo.22802 PMID: 28888073 PMCID: PMC5844851

    Grill JD, Apostolova LG, Bullain S, Burns JM, Cox CG, Dick M, Hartley D, Kawas C, Kremen S, Lingler J, Lopez OL, Mapstone M, Pierce A, Rabinovici G, Roberts JS, Sajjadi SA, Teng E, Karlawish J.Communicating mild cognitive impairment diagnoses with and without amyloid imagingAlzheimers Res Ther. 2017 May 4;9(1):35. doi: 10.1186/s13195-017-0261-y PMID: 28472970 PMCID: PMC5418690

    Guan Y, Roter DL, Wolff JL, Gitlin LN, Christensen KD, Roberts JS, Green RC, Erby LH. The impact of genetic counselors’ use of facilitative strategies on cognitive and emotional processing of genetic risk disclosure for Alzheimer’s disease. Patient education and counseling. 2017 Nov 27. doi: 10.1016/j.pec.2017.11.019 PMID: 29203084 PMCID: PMC5911203

    Gupta R, Lan M, Mojsilovic-Petrovic J, Choi WH, Safren N, Barmada S, Lee MJ, Kalb R.The Proline/Arginine Dipeptide from Hexanucleotide Repeat Expanded <i>C9ORF72</i> Inhibits the Proteasome. eNeuro. 2017 Jan 31, 4(1). pii: ENEURO.0249-16.2017. doi: 10.1523/ENEURO.0249-16.2017. PMID: 28197542 PMCID: PMC5282547

    Hampstead BM, Sathian K, Bikson M, Stringer AY. Combined Mnemonic Strategy Training and High-Definition Transcranial Direct Current Stimulation for Memory Deficits in Mild Cognitive Impairment Alzheimer's & Dementia. Translational Research & Clinical Interventions. 2017, 3(3): 459-470. doi: 10.1016/j.trci.2017.04.008 PMID: 29067352 PMCID: PMC5651427

    Hampstead BM, Towler S, Sathian K, Stringer AY. Continuous measurement of object location memory is sensitive to effects of age and mild cognitive impairment and related to medial temporal lobe volume. Alzheimer's & Dementia: Diagnosis, Assessment and Disease Monitoring. 2017. doi: 10.1016/j.dadm.2017.10.007 PMID: 29255787 PMCID: PMC5724745

    Huang Z, Zhang H, Boss J, Goutman SA, Mukherjee B, Dinov ID, Guan Y; Pooled Resource Open-Access ALS Clinical Trials Consortium. Complete hazard ranking to analyze right-censored data: An ALS survival study. PLoS Comput Biol. 2017 Dec 18;13(12):e1005887. doi: 10.1371/journal.pcbi.1005887 PMID: 29253881 PMCID: PMC5749893

    Jun GR, Chung J, Mez J, Barber R, Beecham GW, Bennett DA, Buxbaum JD, Byrd GS, Carrasquillo MM, Crane PK, Cruchaga C, De Jager P, Ertekin-Taner N, Evans D, Fallin MD, Foroud TM, Friedland RP, Goate AM, Graff-Radford NR, Hendrie H, Hall KS, Hamilton-Nelson KL, Inzelberg R, Kamboh MI, Kauwe JSK, Kukull WA, Kunkle BW, Kuwano R, Larson EB, Logue MW, Manly JJ, Martin ER, Montine TJ, Mukherjee S, Naj A, Reiman EM, Reitz C, Sherva R, St George-Hyslop PH, Thornton T, Younkin SG, Vardarajan BN, Wang LS, Wendlund JR, Winslow AR; Alzheimer's Disease Genetics Consortium, Haines J, Mayeux R, Pericak-Vance MA, Schellenberg G, Lunetta KL, Farrer LA.Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2017 Jul 1;13(7):727-38. doi: 10.1016/j.jalz.2016.12.012 PMID: 28183528 PMCID: PMC5496797

    Kalinin AA, Palanimalai S, Dinov ID. SOCRAT Platform Design: A Web Architecture for Interactive Visual Analytics Applications. Proceedings of the 2nd Workshop on Human-In-the-Loop Data Analytics. Workshop on Human-In-the-Loop Data Analytics (2nd : 2017 : Chicago, Ill.). 2017 April;2017. PMID: 29630069 PMCID: PMC5884130

    Kelly SC, He B, Perez SE, Ginsberg SD, Mufson EJ, Counts SE. Locus coeruleus cellular and molecular pathology during the progression of Alzheimer's disease. Acta Neuropathological Communications. 2017 Jan 21, 5(1): 8. doi: 10.1186/s40478-017-0411-2. PMID: 28109312 PMCID: PMC5251221

    Kotagal V, Bohnen NI, Müller ML, Frey KA, Albin RL. Cerebral amyloid burden and Hoehn and Yahr stage 3 scoring in Parkinson disease. Journal of Parkinson's disease. 2017 Jan 1;7(1):143-7. doi: 10.3233/JPD-160985 PMID: 28106566 PMCID: PMC5470115

    Langa KM, Larson EB, Crimmins EM, Faul JD, Levine DA, Kabeto MU, Weir DR. A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012. JAMA Internal Medicine. 2017 Jan 1,177(1): 51-58. doi: 10.1001/jamainternmed.2016.6807. PMID: 27893041 PMCID: PMC5195883

    Larson EB, Langa KM. What's the "Take Home" from Research on Dementia Trends? PLoS Med. 2017 Mar 7, 14(3): e1002236. doi: 10.1371/journal.pmed.1002236. PMID: 28267775 PMCID: PMC5340344

    Lichtenberg PA, Ocepek-Welikson K, Ficker LJ, Gross E, Rahman-Filipiak A, Teresi JA. Conceptual and empirical approaches to financial decision-making by older adults: Results from a financial decision-making rating scale. Clinical gerontologist. 2018 Jan 1;41(1):42-65. doi: 10.1080/07317115.2017.1367748 PMID: 29077531 PMCID: PMC5766370

    Lichtenberg P, Teresi JA, Ocepek-Welikson K, JosEimicke JP. Reliability and Validity of the Lichtenberg Financial Decision Screening Scale. Innovation in Aging. 2017 Mar 1, 00(00): 1–9. doi: 10.1093/geroni/igx003. PMID: 29034335 PMCID: PMC5637552

    Lin M, Gong P, Yang T, Ye J , Albin RL, Dodge HH. Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer's Disease and Associated Disorders. 2017. doi: 10.1097/WAD.0000000000000228 PMID: 29227306 PMCID: PMC5854492

    Lindauer A, Seelye A, Lyons B, Dodge HH, Mattek N, Mincks K, Kaye J, Erten-Lyons D. Dementia Care Comes Home: Patient and Caregiver Assessment via Telemedicine. Gerontologist. 2017 Oct 1, 57(5): e85-e93. doi: 10.1093/geront/gnw206.  PMID: 28158415  PMCID: PMC5654345

    Luo L, Wang J, Lo RY, Figueroa KP, Pulst SM, Kuo PH, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Kuo SH. The Initial Symptom and Motor Progression in Spinocerebellar Ataxias. Cerebellum (London, England). 2017 June;16(3):615-622. doi: 10.1007/s12311-016-0836-3 PMID: 27848087 PMCID: PMC5429172

    Ma X, Bai Y, Lin Y, Hong X, Liu T, Ma L, Haacke EM, Zhou J, Wang J, Wang M. Amide proton transfer magnetic resonance imaging in detecting intracranial hemorrhage at different stages: a comparative study with susceptibility weighted imaging.  Scientific Reports. 2017 Apr 4, 7: 45696. doi: 10.1038/srep45696. PMID: 28374764 PMCID: PMC5379544

    Maust DT, Langa KM, Blow FC, Kales HC. Psychotropic use and associated neuropsychiatric symptoms among patients with dementia in the USA. International Journal of Geriatric Psychiatry. 2017 Feb, 32(2): 164-174. doi: 10.1002/gps.4452. PMID: 26889640 PMCID: PMC4990518

    McEvoy CT, Guyer H, Langa KM, Yaffe K. Neuroprotective Diets Are Associated with Better Cognitive Function: The Health and Retirement Study. Journal of the American Geriatrics Society. 2017 August;65(8):1857-1862. doi: 10.1111/jgs.14922 PMID: 28440854 PMCID: PMC5633651

    McKay E and Counts SE. Multi-infarct dementia: a historical perspective. Dementia and Geriatric Cognitive Disorders Extra. 2017 Jan-Apr, 7(1): 160 - 171. doi: 10.1159/000470836. PMID: 28626470 PMCIDPMC5471781

    Ostergren JE, Heeringa SG, Mendes de Leon CF, Connell CM, Roberts JS*. The influence of psychosocial and cognitive factors on perceived threat of Alzheimer’s disease. American Journal of Alzheimer’s Disease & Other Dementias. 2017. 32(5), 289-99. doi: 10.1177/1533317517714552. PMID: 28605999 PMCID: PMC5886712

    Park SK, Hong JY, Arslan F, Kanneganti V, Patel B, Tietsort A, Tank EMH, Li X, Barmada SJ, Liebman SW. Overexpression of the essential Sis1 chaperone reduces TDP-43 effects on toxicity and proteolysis. PLoS genetics. 2017 May;13(5):e1006805. doi: 10.1371/journal.pgen.1006805 PMID: 28531192 PMCID: PMC5460882

    Poey JL, Burr JA, Roberts JS. Social connectedness, perceived isolation, and dementia: Does the social environment moderate the relationship between genetic risk and cognitive well-being? The Gerontologist. 2017. 57(6), 1031-40. doi: 10.1093/geront/gnw154. PMID: 28329797

    Pressler SJ, Harrison JM, Titler M, Koelling TM, Jung M, Dorsey SG, Bakoyannis G, Riley PL, Hoyland-Domenico L, Giordani B. APOE ε4 and Memory among Patients with Heart Failure Western Journal of Nursing Research. 2017, 39(4): 455-472. doi: 10.1177/0193945916670145 PMID: 27733670

    Qian J, Wolters FJ, Beiser A, Haan M, Ikram MA, Karlawish J, Langbaum JB, Neuhaus JM, Reiman EM, *Roberts JS, Seshadri S, Tariot PN, Woods BM, Betensky RA, Blacker D. APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts. PLoS Med. 2017 Mar 21, 14(3): e1002254. doi: 10.1371/journal.pmed.1002254. PMID: 28323826  PMCID: PMC5360223

    Ramsey CM, Gnjidic D, Agogo GO, Allore H, Moga D. Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimers Dement (N Y). 2017 Nov 26;4:1-10. doi: 10.1016/j.trci.2017.10.008 PMID: 29296658 PMCID: PMC5738721

    Ryan KA, Hammers D, DeLeon A, Bilen H, Frey K, Burke J, Albin R, Barbas N, Heidebrink J, Giordani B. Agreement among neuropsychological and behavioral data and PiB findings in diagnosing Frontotemporal Dementia. Journal of Clinical Neuroscience. 2017 Jun 7. pii: S0967-5868(17)30253-9. doi: 10.1016/j.jocn.2017.05.008. PMCID: PMC5581998  PMID: 28601570

    Sims R, Van Der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, Martin ER. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature genetics. 2017 Sep;49(9):1373. doi: 10.1038/ng.3916 PMID: 28714976 PMCID: PMC5669039

    Song W, Woon FL, Doong A, Persad C, Tijerina L, Pandit P, Cline C, Giordani B.  Fatigue in Younger and Older Drivers:  Effectiveness of an Alertness Maintaining Task.  Human Factors. 2017 Sept, 59(6): 995–1008. doi: 10.1177/0018720817706811 PMID: 28510495

    Sorrentino V, Romani M, Mouchiroud L, Beck JS, Zhang H, D'Amico D, Moullan N, Potenza F, Schmid AW, Rietsch S, Counts SE, Auwerx J. Enhancing mitochondrial proteostasis reduces amyloid-β proteotoxicity. Nature. 2017 December 14;552(7684):187-193. doi: 10.1038/nature25143 PMID: 29211722 PMCID: PMC5730497

    Stelmokas J, Yassay L, Giordani B, Dodge HH, Dinov ID, Bhaumik A, Sathian K, Hampstead BM. Translational MRI Volumetry with NeuroQuant: Effects of Version and Normative Data on Relationships with Memory Performance in Healthy Older Adults and Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease. 2017, 60; 1499-1510. doi: 10.3233/JAD-170306 PMID: 29060939 PMCID: PMC5858697

    Tarraf W, Rodríguez CJ, Daviglus ML, Lamar M, Schneiderman N, Gallo L, Talavera GA, Kaplan RC, Fornage M, Conceicao A, González HM. Blood Pressure and Hispanic/Latino Cognitive Function: Hispanic Community Health Study/Study of Latinos Results. Journal of Alzheimer's disease : JAD. 2017;59(1):31-42. doi: 10.3233/JAD-170017 PMID: 28582859 PMCID: PMC5567691

    Teresi JA, Ocepek-Welikson K, Lichtenberg PA. Item response theory analysis of the Lichtenberg Financial Decision Screening Scale. Journal of elder abuse & neglect. 2017 August;29(4):213-228. doi: 10.1080/08946566.2017.1338170 PMID: 28590882 PMCID: PMC5608641

    Vega IE, Cabrera LY, Wygant CM, Velez-Ortiz D, Counts SE. Alzheimer's Disease in the Latino Community: Intersection of Genetics and Social Determinants of Health. J Alzheimers Dis. 2017. 58(4):979-992. doi: 10.3233/JAD-161261 PMID: 28527211 PMCID: PMC5874398.

    Weintraub S, Besser L, Dodge HH, Teylan M, Ferris S, Goldstein FC,  Giordani B, Kramer J,  Loewenstein D, Marson D, Mungas D, Salmon D, Welsh-Bohmer K, Zhou X-H, Shirk SD, Atri A, Kukull WA, Phelps C, Morris JC. Version 3 of the Alzheimer's Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS) Change. Alzheimer Disease and Associated Disorders. 2017. doi: 10.1097/WAD.0000000000000223 PMID: 29240561 PMCID: PMC5821520

    Yeh AN, Pressler S, Algasse D, Struble L, Giordani B. Integrative review of the relationship between sleep disturbances and episodic memory in older adults, Biological Research for Nursing, Accepted for Publication, 2017.


       Krans A, Kearse MG, Todd PK.Repeat-associated non-AUG translation from antisense CCG repeats in fragile X tremor/ataxia syndrome. Ann Neurol. 2016 Dec, 80(6): 871-881. doi: 10.1002/ana.24800 PMID: 27761921 PMCID: PMC5177492

    Chun SY, Rodriguez CM, Todd PK, Mills RESPECtre: a spectral coherence—based classifier of actively translated transcripts from ribosome profiling sequence data. BMC Bioinformatics. 2016 Nov 25, 17(1): 482. doi: 10.1186/s12859-016-1355-4 PMID: 27884106 PMCID: PMC5123373

    Flores BN, Dulchavsky ME, Krans A, Sawaya MR, *Paulson HL, Todd PK, Barmada SJ, Ivanova MIDistinct C9orf72-Associated Dipeptide Repeat Structures Correlate with Neuronal Toxicity.PLoS One. 2016 Oct 24, 11(10): e0165084. doi: 10.1371/journal.pone.0165084 PMID: 27776165 PMCID: PMC5077081

    Amiri S, *Dinov ID.  Comparison of genomic data via statistical distributionJ Theor Biol. 2016 Oct 21, 407: 318-27. doi: 10.1016/j.jtbi.2016.07.032 PMID: 27460589 PMCID: PMC5361063

    Dodge HH, Zhu J, Hughes TF, Snitz BE, Chang CH, Jacobsen EP, Ganguli M.Cohort effects in verbal memory function and practice effects: a population-based study.* Int Psychogeriatr. 2017 Jan, 29(1): 137-148. doi: 10.1017/S1041610216001551 PMID: 27725002 PMCID: PMC5177461

    Bikson M, Grossman P, Thomas C, Zannou AL, Jiang J, Adnan T, Mourdoukoutas AP, Kronberg G, Truong D, Boggio P, Brunoni AR, Charvet L, Fregni F, Fritsch B, Gillick B, Hamilton RH, *Hampstead BM, Jankord R, Kirton A, Knotkova H, Liebetanz D, Liu A, Loo C, Nitsche MA, Reis J, Richardson JD, Rotenberg A, Turkeltaub PE, Woods AJ. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimul. 2016 Sep-Oct, 9(5): 641-61. doi: 10.1016/j.brs.2016.06.004. PMID: 27372845 PMCID: PMC5007190

    Counts SE, He B, Prout JG, Michalski B, Farotti L, Fahnestock M, Mufson EJ. Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer's Disease. Current Alzheimer research. 2016;13(7):800-8. PMID: 26825093

    Díaz-Venegas C, Downer B, Langa KM, Wong RRacial and ethnic differences in cognitive function among older adults in the USA. International Journal of Geriatric Psychiatry. 2016 Sep, 31(9): 1004-12. doi: 10.1002/gps.4410 PMID: 26766788 PMCID: PMC4945484

    Dodge HH, Zhu J, Woltjer R, Nelson PT, Bennett DA, Cairns NJ, Fardo DW, Kaye JA, Lyons DE, Mattek N, Schneider JA, Silbert LC, Xiong C, Yu L, Schmitt FA, Kryscio RJ, Abner EL. Risk of incident clinical diagnosis of Alzheimer’s disease-type dementia attributable to pathology-confirmed vascular disease. SMART data consortium. Alzheimers Dement. 2016 Dec 23, 13(6): 613-623. pii: S1552-5260(16)33091-6. doi: 10.1016/j.jalz.2016.11.003 PMID: 28017827 PMCID: PMC5466467  

    Hammers D, Ramirez G, Persad C, Heidebrink J, Barbas N, Giordani B. Diagnostic profiles of patients differentially failing executive functioning measures. American Journal of Alzheimer’s Disease & Other Dementias. 2016, 31(3): 214-222. doi: 10.1177/1533317515603114 PMID: 26340963

     Ivo D. Dinov. Methodological challenges and analytic opportunities for modeling and interpreting Big Healthcare Data. GigaScience. 2016 Dec, 5(1): 1-15. doi: 10.1186/s13742-016-0117-6 PMID: 26918190 PMCID: PMC4766610

    Karlawish J, Langa KM. Unfinished Business in Preventing Alzheimer Disease. JAMA internal medicine. 2016 December 1;176(12):1739-1740. doi: 10.1001/jamainternmed.2016.6310 PMID: 27749947 PMCID: PMC5458728

    Kavcic V, Zalar B, Giordani B. The relationship between baseline EEG spectra power and memory performance in older African Americans endorsing cognitive concerns in a community setting. International Journal of Psychophysiology. 2016, 109: 116-123. doi: 10.1016/j.ijpsycho.2016.09.001 PMID: 27613569

    Monsell SE, Dodge HH, Zhou X, Bu Y, Besser LM, Mock C, Hawes SE, Kukull WA, Weintraub S. Results From the NACC Uniform Data Set Neuropsychological Battery Crosswalk Study. Alzheimer Disease & Associated Disorders. 2016 Apr-Jun, 30(2): 134-139. doi: 10.1097/WAD.0000000000000111 PMID: 26485498 PMCID: PMC4834278

     Votruba KL, Persad C, Giordani B. Cognitive deficits in healthy elderly population with “normal” scores on the mini-mental state examination. Journal of Geriatric Psychiatry and Neurology. 2016, 29(3): 126-132. doi: 10.1177/0891988716629858 PMID: 26850856

     Zhu F, Panwar B, *Dodge HH, Li H, *Hampstead BM, *Albin RL,* Paulson HL, Guan, Y.COMPASS: A computational model to predict changes in MMSE scores 24-months after initial assessment of Alzheimer's disease.  Sci Rep. 2016 Oct 5, 6: 34567. doi: 10.1038/srep34567 PMID: 27703197 PMCID: PMC5050516

    Zhang J, Shi J, Stonnington C, Li Q, Gutman BA, Chen K, Reiman EM, Caselli RJ, Thompson PM, Ye J, Wang Y. Hyperbolic Space Sparse Coding with Its Application on Prediction of Alzheimer's Disease in Mild Cognitive Impairment.  Medical Image Comput Comput Assist Interv. 2016 Oct, 9900: 326-334. doi: 10.1007/978-3-319-46720-7_38 PMID: 28066843 PMCID: PMC5217478

    Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, McDade E, Ringman JM, Thompson PM, Saykin AJ, Ghetti B, Sperling RA, Johnson KA, Salloway SP, Schofield PR, Masters CL, Villemagne VL, Fox NC, Förster S, Chen K, Reiman EM, Xiong C, Marcus DS, Weiner MW, Morris JC, Bateman RJ, Benzinger TLCorrection: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. Dominantly Inherited Alzheimer Network. PLoS One. 2016 Sep 20, 11(9): e0163669. doi: 10.1371/journal.pone.0163669 PMID: 27649320 PMCID: PMC5029931

    Mufson EJ, Ikonomovic MD, Counts SE, Perez SE, Malek-Ahmadi M, Scheff SW, Ginsberg SD. Molecular and cellular pathophysiology of preclinical Alzheimer's disease. Behavioral Brain Research. 2016 Sep 15, 311: 54-69. doi: 10.1016/j.bbr.2016.05.030 PMID: 27185734 PMCID: PMC4931948

    Gawronski KA, Kim ES, Langa KM, Kubzansky LD. Dispositional Optimism and Incidence of Cognitive Impairment in Older Adults. Psychosomatic Medicine. 2016 Sep, 78(7): 819-28. doi: 10.1097/PSY.0000000000000345 PMID: 27284699 PMCID: PMC5349707

    Promjunyakul NO, Lahna DL, Kaye JA, *Dodge HH, Erten-Lyons D, Rooney WD, Silbert LC.Comparison of cerebral blood flow and structural penumbras in relation to white matter hyperintensities: A multi-modal magnetic resonance imaging study.  Journal of Cerebral Blood Flow Metabolism. 2016 Sep, 36(9): 1528-36. doi: 10.1177/0271678X16651268. Epub 2016 Jun 7. doi: 10.1177/0271678X16651268 PMID: 27270266 PMCID: PMC5010096

    Reams N, Eckner JT, Almeida AA, Aagesen AL, *Giordani B, *Paulson H, Lorincz MT, Kutcher JS. A clinical approach to the diagnosis of traumatic encephalopathy syndrome: A review.  Journal of the American Medical Association: Neurology. 2016, 73(6): 734-749. doi: 10.1001/jamaneurol.2015.5015 PMID: 27111824 PMCID: PMC4922002


    Gabel NM, Crane NA, Avery ET, Kay RE, Laurent A, Giordani B, Alexander NB, Weisenbach SL. Dual-tasking gait variability and cognition in late-life depression. Int J Geriatr Psychiatry. 2015 Nov, 30(11): 1120-8. doi: 10.1002/gps.4340 PMID: 26251013

    Albin RL, Fisher-Hubbard A, Shanmugasundaram K, Koeppe RA, Burke JF, Camelo-Piragua S, Lieberman AP, Giordani B, Frey KA. Post-mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications. Ann Neurol. 2015 Nov, 78(5): 824-30. doi: 10.1002/ana.24481. PMID: 26183692 PMCIDPMC4836870

    Mufson EJ, Mahady L, Waters D, Counts SE, Perez SE, DeKosky ST, Ginsberg SD, Ikonomovic MD, Scheff SW, Binder L. Hippocampal plasticity during the progression of Alzheimer’s disease. Neuroscience. 2015 Nov 19, 309: 51-67. doi: 10.1016/j.neuroscience.2015.03.006. PMID: 25772787 PMCID: PMC4567973

    Sachdev PS, Lipnicki DM, Kochan NA, Crawford JD, Thalamuthu A, Andrews G, Brayne C, Matthews FE, Stephan BC, Lipton RB, Katz MJ, Ritchie K, Carrière I, Ancelin ML, Lam LC, Wong CH, Fung AW, Guaita A, Vaccaro R, Davin A, Ganguli M, Dodge H1, Hughes T, Anstey KJ, Cherbuin N, Butterworth P, Ng TP, Gao Q, Reppermund S, Brodaty H, Schupf N, Manly J, Stern Y, Lobo A, Lopez-Anton R, Santabárbara J. The prevalence of mild cognitive impairment in diverse geographical and ethnocultural regions: the COSMIC collaboration. PLoS One. 2015 Nov 5, 10(11): e0142388. doi: 10.1371/journal.pone.0142388 PMID: 26539987 PMCID: PMC4634954

    Friedman EM, Shih RA, Langa KM, Hurd MD.US prevalence and predictors of informal caregiving for dementia. Health Aff (Millwood). 2015 Oct, 34(10): 1637-41. doi: 10.1377/hlthaff.2015.0510 PMID: 26438738 PMCID: PMC4872631

    Beach PA, Huck JT, Miranda MM, Bozoki AC. Autonomic, behavioral, and subjective pain responses in Alzheimer’s disease. Pain Med. 2015 Oct;16(10):1930-42. doi: 10.1111/pme.12769 PMID: 25929320

    Beach PA, Huck JT, Miranda MM, Bozoki AC. Factors associated with cognitive evaluations in the United States. Pain Med. 2015 Oct, 16(10): 1930-42. doi: 10.1111/pme.12769 PMID: 25929320 PMCID: PMC4336093

    Lichtenberg PA, Ficker LJ, Rahman-Filipiak A. Financial decision-making abilities and exploitation in older African Americans: Preliminary validity evidence for the Lichtenberg Financial Decision Rating Scale (LFDRS). J Elder Abuse Negl. 2016, 28(1): 14-33. doi: 10.1080/08946566.2015.1078760 PMID: 26285038 PMCID: PMC4740256

    Oh SY, He F, Krans A, Frazer M, Taylor JP, Paulson HL, Todd PK. RAN translation at CGG repeats induces ubiquitin proteasome system impairment in models of fragile X-associated tremor ataxia syndrome. Hum Mol Genet. 2015 Aug 1, 24(15): 4317-26. doi: 10.1093/hmg/ddv165 PMID: 25954027 PMCID: PMC4492395

    Votruba KL, Persad C, Giordani B. Patient mood and instrumental activities of daily living in Alzheimer disease: Relationship between patient and caregiver reports. J Geriatr Psychiatry Neurol. 2015 Sep, 28(3): 203-9. doi: 10.1177/0891988715588829 PMID: 26071443

    Levine DA, Galecki AT, Langa K3, Unverzagt FW, Kabeto MU, Giordani B, Wadley VG. Trajectory of cognitive decline after incident stroke. JAMA. 2015 Jul 7, 314(1): 41-51. doi: 10.1001/jama.2015.6968 PMID: 26151265 PMCIDPMC4655087

    Kotagal V, Bohnen NI, Müller ML, Koeppe RA, Frey KA, Langa KM, Albin RL. Educational attainment and motor burden in Parkinson’s disease. Mov Disord. 2015 Jul, 30(8): 1143-7. doi: 10.1002/mds.26272 PMID: 26096339 PMCID: PMC4504749

    Barmada SJ, Ju S, Arjun A, Batarse A, Archbold HC, Peisach D, Li X, Zhang Y, Tank EM, Qiu H, Huang EJ, Ringe D, Petsko GA, Finkbeiner S. Amelioration of toxicity in neuronal models of amyotrophic lateral sclerosis by hUPF1. Proc Natl Acad Sci U S A. 2015 Jun 23, 112(25): 7821-6. doi: 10.1073/pnas.1509744112 PMID:26056265 PMCIDPMC4485101

    Østergaard SD, Mukherjee S, Sharp SJ, Proitsi P, Lotta LA, Day F, Perry JR, Boehme KL, Walter S, Kauwe JS, Gibbons LE; Alzheimer’s Disease Genetics Consortium; GERAD1 Consortium; EPIC-InterAct Consortium, Larson EB, Powell JF, Langenberg C, Crane PK, Wareham NJ, Scott RA. Associations between potentially modifiable risk factors and Alzheimer disease: A Mendelian Randomization Study. PLoS Med. 2015 Jun 16, 12(6): e1001841; discussion e1001841. doi: 10.1371/journal.pmed.1001841 PMID: 26079503 PMCIDPMC4469461

    Fyock CA, Hampstead BM. Comparing the relationship between subjective memory complaints, objective memory performance, and medial temporal lobe volumes in patients with mild cognitive impairment. Alzheimers Dement (Amst). 2015 Jun 1, 1(2): 242-248. doi: 10.1016/j.dadm.2015.03.002 PMID: 26191540 PMCID: PMC4501028

    Monsell SE, Dodge HH, Zhou XH, Bu Y, Besser LM, Mock C, Hawes SE, Kukull WA, Weintraub S; Neuropsychology Work Group Advisory to the Clinical Task Force. Results from the NACC Uniform Data Set Neuropsychological Battery Crosswalk Study. Alzheimer Dis Assoc Disord. 2016 Apr-Jun, 30(2): 134-9. doi: 10.1097/WAD.0000000000000111 PMID: 26485498 PMCID: PMC4834278

    Atkin G, Moore S, Lu Y, Nelson RF, Tipper N, Rajpal G, Hunt J, Tennant W, Hell JW, Murphy GG, Paulson H. Loss of F-box only protein 2 (Fbxo2) disrupts levels and localization of select NMDA receptor subunits, and promotes aberrant synaptic connectivity. J Neurosci. 2015 Apr 15, 35(15): 6165-78. doi: 10.1523/JNEUROSCI.3013-14.2015 PMID: 25878288 PMCIDPMC4397610

    Langa KM. Is the risk of Alzheimer’s disease and dementia declining? Alzheimers Res Ther. 2015 Mar 26, 7(1): 34. doi: 10.1186/s13195-015-0118-1 PMID: 25815064 PMCID: PMC4374373

    Jun G, Ibrahim-Verbaas CA, Vronskaya M, Lambert JC, Chung J, Naj AC, Kunkle BW, Wang LS, Bis JC, Bellenguez C, Harold D, Lunetta KL, Destefano AL, Grenier-Boley B, Sims R, Beecham GW, Smith AV, Chouraki V, Hamilton-Nelson KL, Ikram MA, Fievet N, Denning N, Martin ER, Schmidt H, Kamatani Y, Dunstan ML, Valladares O, Laza AR, Zelenika D, Ramirez A, Foroud TM, Choi SH, Boland A, Becker T, Kukull WA, van der Lee SJ, Pasquier F, Cruchaga C, Beekly D, Fitzpatrick AL, Hanon O, Gill M, Barber R, Gudnason V, Campion D, Love S, Bennett DA, Amin N, Berr C, Tsolaki M, Buxbaum JD, Lopez OL, Deramecourt V, Fox NC, Cantwell LB, Tárraga L, Dufouil C, Hardy J, Crane PK, Eiriksdottir G, Hannequin D, Clarke R, Evans D, Mosley TH Jr, Letenneur L, Brayne C, Maier W, De Jager P, Emilsson V, Dartigues JF, Hampel H, Kamboh MI, de Bruijn RF, Tzourio C, Pastor P, Larson EB, Rotter JI, O'Donovan MC, Montine TJ, Nalls MA, Mead S, Reiman EM, Jonsson PV, Holmes C, St George-Hyslop PH, Boada M, Passmore P, Wendland JR, Schmidt R, Morgan K, Winslow AR, Powell JF, Carasquillo M, Younkin SG, Jakobsdóttir J, Kauwe JS, Wilhelmsen KC, Rujescu D, Nöthen MM, Hofman A, Jones L; IGAP Consortium, Haines JL, Psaty BM, Van Broeckhoven C, Holmans P, Launer LJ, Mayeux R, Lathrop M, Goate AM, Escott-Price V, Seshadri S, Pericak-Vance MA, Amouyel P, Williams J, van Duijn CM, Schellenberg GD, Farrer LA.A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry. 2016 Jan, 21(1): 108-17. doi: 10.1038/mp.2015.23. PMID: 25778476 PMCID: PMC4573764

    Moon SW, Dinov ID, Kim J, Zamanyan A, Hobel S, Thompson PM, Toga AW. Structural neuroimaging genetics interactions in Alzheimer’s Disease. J Alzheimers Dis. 2015, 48(4): 1051-63. doi: 10.3233/JAD-150335 PMID: 26444770 PMCIDPMC4730943

    Beck JS, Mufson EJ, Counts SE. Evidence for mitochondrial UPR gene activation in familial and sporadic Alzheimer’s disease. Curr Alzheimer Res. 2016, 13(6): 610-4. PMID: 26687188

    Moon SW, Dinov ID, Zamanyan A, Shi R, Genco A, Hobel S, Thompson PM, Toga AW; Alzheimer's Disease Neuroimaging Initiative (ADNI). Gene interactions and structural brain change in early-onset Alzheimer’s disease subjects using the pipeline environment. Psychiatry Investig. 2015 Jan, 12(1): 125-35. doi: 10.4306/pi.2015.12.1.125 PMID: 25670955 PMCIDPMC4310910

    Hampstead BM, Khoshnoodi M, Yan W, Deshpande G, Sathian K.Patterns of effective connectivity during memory encoding and retrieval differ between patients with mild cognitive impairment and healthy older adults. Neuroimage. 2016 Jan 1, 124(Pt A): 997-1008. doi: 10.1016/j.neuroimage.2015.10.002 PMID: 26458520

    Paulson D, Lichtenberg PA. The Paulson-Lichtenberg Frailty Index: evidence for a self-report measure of frailty. Aging Ment Health. 2015, 19(10): 892-901. doi: 10.1080/13607863.2014.986645 PMID: 25537004 PMCID: PMC4480217

  • Professional Resources

    We support the work of investigators and other professionals in a variety of ways. Please review our various methods of support below, and contact us if you have any questions. Please be sure to acknowledge the partial support of our funding in all work to which we contribute. Specific acknowledgement information is listed in the Acknowledgement & Logos section below.

    Questions should be directed to Ari Bhaumik at arijit@med.umich.edu or 734-936-8281.

    Recruitment Resources

    Our Center promotes clinical research on memory and aging that involves direct use of research volunteers, biomarkers, and other clinical data collected through the University of Michigan Memory and Aging Project. We manage a well-characterized data set to facilitate recruitment for Center-supported projects and publications.

    For more information, contact Arijit Bhaumik at 734-936-8281 or arijit@med.umich.edu.

    Clinical Resources

    Investigators wishing to utilize the research volunteer database must complete the Clinical Resource Application (PDF).

    For more information, contact Arijit Bhaumik at 734-936-8281 or arijit@med.umich.edu.

    Data Resources

    For preliminary data requests, please complete and submit the Data Request Form.

    For more information, contact Arijit Bhaumik at 734-936-8281 or arijit@med.umich.edu.

    Brain Tissue Resources

    The Michigan Brain Bank is designed to support investigations of dementing disorders.  The Michigan Brain Bank provides researchers who study Alzheimer’s disease and related disorders with access to well-characterized human brain tissue. To optimize research, the Michigan Brain Bank assists in the collection and storage of brain tissue from individuals who have been followed in research studies at the University of Michigan and other Centers. We are fortunate to have had many generous patients and families participate in this brain donation program. The most useful tissue for research comes from individuals with extensive clinical information, typically from those who have participated in clinical research projects. Tissues stored in the Michigan Brain Bank are extensively characterized by experienced pathologists and available to scientists on request.  Michigan Brain Bank tissues have been used by numerous scientists here and at other Centers in the United States.

    For investigators wishing to utilize tissues stored in the Michigan Brain Bank, please visit the Michigan Brain Bank website to download and submit tissue resource applications.  Investigators may also download the Tissue Resource Application and submit it via mail.

    For further information, please contact Matthew Perkins at UMHSbrainbank@med.umich.edu or 734-647-7648.

    "Dementia for Scientists" Online Curriculum

    The Michigan Alzheimer’s Disease Research Center was pleased to release the “Dementia for Scientists” online curriculum in September 2018.  The curriculum is available to view on YouTube here. The goal of this curriculum is to provide a broad and current introduction to important aspects of dementias and dementia-related research.  The target audience is junior investigators.

    Why did we create this curriculum? Dementia research is highly diverse in content, ranging from basic biophysical research to social science.  While investigators entering the field from diverse research backgrounds are well-trained in their own discipline, they may lack broader knowledge of the many aspects of dementia and dementia research that are important in understanding critical issues in the field.  This curriculum aims to provide a relatively sophisticated introduction to critical aspects of dementias across the broad sweep of the field.  The ultimate goal is to enhance the ability of junior investigators to read and understand relevant literature outside their own disciplines.

    The curriculum consists of 7 modules, each of which addresses an important area in contemporary dementia research.  Each module includes several presentations.  The presentations are relatively concise, PowerPoint lectures that can be viewed when convenient.

    The modules include the following topics:

    • Dementia Definition and Evaluation
    • Dementia Pathology & Pathogenesis
    • Dementia Genetics
    • Dementia Imaging
    • Therapy Development in Dementias
    • Health Services and Policy Dementia Research
    • Research Performance in Ethnically Diverse Populations

    We encourage users to view all modules, though many may wish to focus on topics outside their areas of expertise.  Modules 1, 2, 5, & 6 might be said to constitute core elements that everyone should know.

    We hope you find the curriculum valuable. This is our initial effort and we welcome all comments, criticisms, and suggestions. Please send all feedback to Erin Fox at eefox@med.umich.edu.

    If you would like to share the curriculum with others, a promotional flyer is available here: Curriculum Flyer

    Link to the ‘Dementia for Scientists” Online Curriculum 

    Web-based Certificate in Advanced Clinical Dementia Practice

    Several Center faculty were involved in the creation of this University of Michigan School of Social Work certificate program

    This self-paced certificate is designed for healthcare professionals who deliver or plan to deliver person- and family-centered care to people living with memory loss or dementia, including: social workers; nurses; primary care physicians; physical therapists; occupational therapists; health educators; and administrators. Participants will gain clinical knowledge and skills in culturally-competent assessment, care planning, and state-of-the-art clinical intervention.

    Learn more about the program here.

    Junior Investigator Mentorship Program

    The Michigan Alzheimer’s Disease Research Center offers a mentoring program for junior investigators.  The program aims to provide junior investigators entering the field of dementia research with a broad education about contemporary dementia research and provide junior investigators with mentoring by experienced investigators in developing competitive grant applications. The program lasts for two years and includes the following components:

    • An online curriculum about contemporary dementia research to introduce mentees to the basic features of the dementias.
    • An individually tailored mentoring committee of experienced investigators to assist mentees with preparation of competitive grant applications.
    • Participation in the career development workshop jointly sponsored by the Michigan Alzheimer's Disease Research Center rand the University of Michigan Pepper Center.  This workshop takes place in the spring and includes a mock study section and other career development activities.
    • Mentees receive preferred (not guaranteed) access to Michigan Alzheimer's Disease Research Center resources and Pilot Project programs.

    Eligibility Criteria Include:

    • Career commitment to dementia-related research.  This covers the whole spectrum of research from social science work to basic biology.
    • Post-doctoral fellow or junior faculty status.
    • Realistic plans to submit a grant application within the next 2 years.
    Pilot Project Program

    As we seek to understand and cure Alzheimer’s disease and related dementias, we consider it among our highest priorities to support innovative, high impact research. Our Center’s Pilot Project Program provides “kick-starter” funds to investigators so that they can begin testing new ideas about the causes and treatment of dementias. We are committed to funding $35,000 pilot projects per year, open to any investigators at the University of Michigan, Michigan State University, Wayne State University, and the Ann Arbor VA.

    More information on the previous pilot projects funded by our Center is available under the "More" tab above.

    Mezey Travel Award Program

    The Michigan Alzheimer’s Disease Center is committed to promoting the advancement of dementia research skills in junior faculty through the provision of training resources. Established with the generous support of the Chawla family, the Isadore & Margaret Mezey award will pay for travel expenses for three junior investigators associated with their participation in national or international conferences focusing on the latest discoveries in neurodegenerative research and clinical practices. Awardees have a keen interest in advancing their careers in the dementia field and use the award for participation in annual meetings associated with major brain-related associations or societies.

    Call for applications to the Mezey Travel Awards takes place twice per year.

    Acknowledgement & Logos

    Please remember to acknowledge partial support from NIH/NIA grant 5P30AG053760 in your publications, presentations, websites, posters, and other dissemination efforts that are related to our Center’s research, development and training activities. Also, please include an approved Center logo.

    Text must read:

    This <project/study (choose one)> was partially supported by the NIH/NIA funded Michigan Alzheimer’s Disease Center (5P30AG053760).


    For approved logos to use in posters and presentations, please contact Renee Gadwa at rgadwa@med.umich.edu.

  • The Pilot Project Program

    As we seek to understand and cure Alzheimer’s disease and related dementias, we consider it among our highest priorities to support innovative, high impact research. Our Center’s Pilot Project Program provides “kick-starter” funds to investigators so that they can begin testing new ideas about the causes and treatment of dementias. We are committed to funding $35,000 pilot projects per year, open to any investigators at the University of Michigan, Michigan State University, Wayne State University, and the Ann Arbor VA.

    2018-2019 Funded Pilot Projects

    "Characterization of faster onset of Alzheimer’s disease within mild cognitive impairment patients by brain functional connectivity and genetic variants"

    Eunjee Lee, PhD (University of Michigan) and Chandra Sripada, PhD (University of Michigan)

    Goal: To uncover multi-model brain functional connectivity/gene markers of shorter conversion time from MCI to AD by constructing advanced Bayesian low rank models.

    Dr. Eunjee Lee is a Research Assistant Professor of Biostatistics at the University of Michigan. Her research interests lie in developing statistical methods to explore biomedical data, such as brain imaging and genetic data. Her current work is focused on Bayesian methods for functional data analysis, matrix decomposition, and variable selection in high-dimensional settings.

    Dr. Chandra Sripada is an Associate Professor of Psychiatry and an Associate Professor of Philosophy at the University of Michigan. His research examines agency, attention, and self-control from cross-disciplinary perspectives.

    "Cortical Microstructural Changes in African-Americans with Alzheimer’s Disease"

    Navid Seraji-Bozorgzad, MD (University of Michigan) and Rohit Marawar, MD (Wayne State University)

    Goal: To examine the cortical microstructure as reflected by two novel MRI techniques, Neurite Orientation Dispersion and Density Imaging (NODDI) and Diffusion Kurtosis Imaging (DKI) in a cohort of African American and White patients with early Alzheimer’s disease.

    Dr. Seraji-Bozorgzad is an Assistant Professor of Neurology at the University of Michigan. The interaction of body and brain in disease state are of particular interest to him, both in terms of neurological manifestations of systemic disease, and effect of neurological disease on other systems. His research experience is in the field of MR imaging. He is interested in biomarkers of brain injury and repair, as it applies to various degenerative disorders, including Alzheimer’s disease.

    Dr. Rohit Marawar is an Assistant Professor of Neurology at Wayne State University. Dr. Marawar’s expertise and training is in the field of epilepsy. Recently, he transitioned his focus into hyperexcitable brain networks in cognitively normal and abnormal elderly – including those with Alzheimer’s disease and related dementias. Dr. Marawar contributed to the development of the Geriatric Epilepsy Clinic at Wayne State University-Detroit Medical Center.

    “RNA binding protein sequestration in Non-Amyloid Dementia”

    Peter Todd, MD, PhD (University of Michigan)

    Goal: To leverage emerging technologies to identify novel repeat associated RNA-binding proteins (RBPs) and then evaluate their roles in two common genetic forms of dementia: C9orf72-associated frontotemporal dementia (C9FTD) and fragile X-associated tremor/ataxia syndrome (FXTAS).

    Dr. Peter Todd is the Bucky and Patti Harris Career Development Professor of Neurology and an Associate Professor of Neurology at the University of Michigan. His research explores the molecular mechanisms in neurodegenerative diseases with a particular interest in repeat expansion diseases such as the recently discovered C9ORF72 expansion underlying frontotemporal dementia. Dr. Todd is also a staff neurologist at the Ann Arbor VA Medical Center. He has worked in the field of Fragile X research for almost 20 years.

    “Inflammation, social stress, and racial disparities in cognitive aging”

    Laura Zahodne, PhD (University of Michigan)

    Goal: To test the overarching hypothesis that racially-patterned social stress (discrimination) partially explains disparities in cognitive health through its effects on inflammation. In addition, this study will test whether associations among race, social stress, inflammation, and cognition differ according to socioeconomic status and quantify effects of examiner-examinee racial discordance on cognitive performance.

    Dr. Laura Zahodne is a clinical neuropsychologist and an Assistant Professor of Psychology at the University of Michigan. Her research interests include psychosocial factors in aging and neurodegenerative disease, psychosocial factors and racial/ethnic diversity in cognitive aging, and statistical modeling of symptom trajectories in aging and neurodegenerative disease.

    2017-2018 Funded Pilot Projects

    "Hippocampal Connectivity Along The Spectrum of Pre-clinical Alzheimer’s Disease"

    Jessica Damoiseaux, PhD

    Assistant in the Institute of Gerontology and the Department of Psychology at Wayne State University

    Goal: To determine the difference in hippocampal functional and structural connectivity among older adults along the putative preclinical spectrum from healthy to subjective cognitive impairment (SCI) and mild cognitive impairment (MCI), and its association with objective cognitive performance.

    Outcome: Project is ongoing.

    "Determine The Role of the Novel EFhd2 Protein on Tau Oligomerization"


    Irving Vega, PhD

    Associate Professor of Translational Science & Molecular Medicine at Michigan State University



    Magdalena Ivanova, PhD

    Research Assistant Professor of Neurology and Adjunct Assistant Professor of Biophysics at the University of Michigan

    Goal: To understand the role of EFhd2 as a putative modulator of tau oligomerization, in a collaborative effort between researchers at Michigan State University and University of Michigan.

    Outcome: Project is ongoing.


    "Leveraging Longitudinal Electronic Health Records for the Characterization of the Progression of Alzheimer's Disease"

    Jenna Wiens, PhD

    Assistant Professor in Computer Science Engineering (CSE) at the University of Michigan

    Goal: The development of methods for leveraging University of Michigan Health System and VA Health Administration Electronic Health Record data for novel retrospective analyses of patient trajectories prior to and following a diagnosis with MCI and AD.

    Outcome: Project is ongoing.

    "Defining RNA-based Mechanisms of Neurodegeneration in FTLD-TDP"

    Sami Barmada, MD, PhD

    Associate Professor of Neurology at the University of Michigan

    Goal: To determine the importance of TDP43’s RNA binding domains to neurotoxicity, and to define the TDP43 targets that most closely associate with neurodegeneration in frontotemporal dementia models.

    Outcome: Project is ongoing.

    This project is funded by the Erb Family Foundation Grant

    2015 Funded Pilot Projects

    “Decision Making for Cardiovascular Therapy in Adults with Mild Cognitive Impairment (MCI)”

    Deborah A. Levine, MD, MPH
    Assistant Professor of Internal Medicine and Assistant Professor of Neurology


    Goal: to develop, test, and disseminate strategies to improve the care and clinical decision-making of older patients with MCI

    Outcome: Data from this study was incorporated into an R01 grant application with Dr. Levine as PI which was funded. They are still in the data collection and analysis phase. There are no publications at this time.

    “Screening for novel G4C2 hexanucleotide repeat expansions in neurodegenerative disease”

    Peter K Todd, MD, PhD
    Harris Career Development Professor of Neurology
    Peter Todd
    Goal: To identify novel hexanucleotide repeat expansions as a first step in establishing their roles in the biology of dementia

    Outcome: They did not identify any novel repeat expansions as a cause of ALS or other disorders.

    Publications: He F, Jones JM, Figueroa-Romero C, Zhang D, Feldman EL, Goutman SA, Meisler MH, Callaghan BC, Todd PK. Screening for novel hexanucleotide repeat expansions at ALS- and FTD-associated loci. Neurology Genetics. Volume 2, Issue 3, May 11th 2016, Page 71.

    “Novel approaches to measuring and facilitating the clearance of soluble amyloid from the brain”

    Vikas Kotagal, MD, MS
    Assistant Professor of Neurology

    Goal: To test the primary hypothesis that scalp cooling facilitates the glymphatic system and enhances clearance of soluble A-beta.

    Outcome: Project is currently ongoing. Dr. Kotagal acquired a mentored VA grant this year.

    Publications: There are no publications at this time.

    “Reducing subjective memory complaints in older adults through non-invasive brain stimulation”

    Benjamin Hampstead, PhD
    Associate Professor of Psychiatry, Neuropsychology Section

    Goal: To examine whether tDCS can reduce the severity of SMCs and improve memory test performance in older adults with such complaints.

    Outcome: Project is ongoing.